PHARMACEUTICAL 2024

Bristol Myers Squibb CO
Rank 151 of 309



RealRate

PHARMACEUTICAL 2024

Bristol Myers Squibb CO
Rank 151 of 309

Bristol Myers Squibb

The relative strengths and weaknesses of Bristol Myers Squibb CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bristol Myers Squibb CO compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 81% points.The greatest weakness of Bristol Myers Squibb CO is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 99% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 8.8% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	31,770,000
Cost of Goods Sold	10,693,000
Intangible Assets	48,241,000
Liabilities, Current	22,262,000
Liabilities, Non-Current	43,074,000
Other Assets	8,502,000
Other Compr. Net Income	-280,000
Other Expenses	9,202,000
Other Liabilities	338,000
Other Net Income	0
Other Revenues	45,006,000
Property and Equipment	6,646,000
Research and Development	9,299,000
Selling, General and Administrative Expense	7,772,000

Output Variable	Value in 1000 USD
Assets	95,159,000
Liabilities	65,674,000
Expenses	36,966,000
Revenues	45,006,000
Stockholders Equity	29,485,000
Net Income	8,040,000
Comprehensive Net Income	7,900,000
BaseVar	121,542,500
ECR before LimitedLiability	90%
Economic Capital Ratio	222%